Insider Buying: Entrada Therapeutics Inc (NASDAQ:TRDA) Director Acquires 5,000 Shares of Stock

Entrada Therapeutics Inc (NASDAQ:TRDA) Director John F. Crowley purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 12th. The shares were purchased at an average cost of $9.71 per share, with a total value of $48,550.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ TRDA opened at $8.64 on Friday. The firm has a fifty day moving average of $21.68. Entrada Therapeutics Inc has a fifty-two week low of $8.35 and a fifty-two week high of $36.85.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Wednesday, December 8th. The company reported ($9.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by ($8.91).

TRDA has been the subject of several research reports. Evercore ISI initiated coverage on Entrada Therapeutics in a report on Wednesday, November 24th. They set an “outperform” rating for the company. Cowen started coverage on Entrada Therapeutics in a report on Tuesday, November 23rd. They set an “outperform” rating for the company. Finally, The Goldman Sachs Group started coverage on Entrada Therapeutics in a report on Tuesday, November 23rd. They issued a “neutral” rating and a $29.00 price objective for the company.

Entrada Therapeutics Company Profile

Entrada Therapeutics Inc is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc is based in BOSTON.

Further Reading: Quiet Period Expirations Explained

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.